Clinical-stage drug development company using AI to design psychoactive compounds that target specific emotional and cognitive states for therapeutic use.
Mindstate Design Labs develops programmable psychoactive drugs using its Osmanthus AI platform, which synthesizes 60,000+ human reports of psychoactive drug effects with biochemical data using multi-agent LLMs, Bayesian neural networks, and custom embeddings to map how neurotransmitter receptor combinations produce distinct emotional states. Lead compound MSD-001 is in human studies to demonstrate precision-designed therapeutic emotional and cognitive states (such as empathy, awe, or enhanced aesthetic perception). The MSD-X02 series targets novel CNS mechanisms for select psychoactive effects. Mindstate Design Labs is a product of Mindstate Design Labs.